| Palefsky, Joel Michael |
University Of California, San Francisco
United States |
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations |
3U54CA242646-06S3 |
|
Maria Silvina Frech, Ph.D., M.S. |
| Palesh, Oxana G |
Virginia Commonwealth University
United States |
Multicenter Randomized Controlled Trial of Brief Behavioral Therapy for Cancer Related Insomnia |
5R01CA239714-07 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Panda, Satchidananda |
Salk Institute For Biological Studies
United States |
Impact of Time-Restricted Feeding in Reducing Cancer Risk Through Optimizing Mitochondria Function |
5R01CA258221-05 |
RFA-CA-20-004 (R01 Clinical Trial Optional) |
Nancy J. Emenaker, Ph.D., RDN, LD, FAND |
| Pandharipande, Pari Vijay |
Ohio State University
United States |
Precision Management of Cystic Precursors to Pancreatic Cancer |
5R01CA237133-06 |
|
Matthew Young, Ph.D. |
| Panigrahy, Dipak |
Beth Israel Deaconess Medical Center
United States |
Control of cancer cachexia via stimulation of resolution of inflammation |
5R01CA276107-02 |
|
Marjorie Perloff, M.D. |
| Panikkar, Rajiv |
Geisinger Clinic
United States |
Geisinger Cancer Institute - NCI Community Oncology Research Program (NCORP) |
3UG1CA189847-11S1 |
|
Vanessa A. White, M.P.H. |
| Papachristodoulou, Alexandros |
Rutgers Biomedical And Health Sciences
United States |
Investigating mitochondrial dysfunction in high-risk prostate cancer |
4R00CA276713-03 |
|
Vignesh Gunasekharan, Ph.D. |
| Park, Youngkyu |
Cold Spring Harbor Laboratory
United States |
Preclinical Models for Cancer Therapeutic Development |
5R50CA211506-10 |
|
Marjorie Perloff, M.D. |
| Paulovich, Amanda G |
Fred Hutchinson Cancer Center
United States |
Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environment |
5U2CCA271873-03 |
|
Sidney Fu, M.D. |
| Paulson, Thomas G |
Fred Hutchinson Cancer Center
United States |
The microbiome ecosystem of Barrett's esophagus and progression to cancer |
5R21CA259687-02 |
PAR-20-292 (R21 Clinical Trial Optional) |
Matthew Young, Ph.D. |
